BioTime, Inc. a biotechnology company headquartered in the San Francisco Bay Area, is focused on biomedical research and product development in regenerative medicine.

Our research focuses on developing new therapeutics for age-related degenerative disease. Through our subsidiary companies Cell Cure Neurosciences, OncoCyte, and OrthoCyte, we are developing cell-based therapies for age-related macular degeneration, cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics will use proprietary technology to reverse the developmental aging of human cells and to develop therapies for aging vascular systems.

Using proprietary technology, we have also developed research- and clinical-grade human embryonic stem (hES) cell lines that we market to researchers, scientists, universities, and companies. Our subsidiary ES Cell International (ESI) has developed six hES cell lines that are among the best-characterized and documented lines available today. These lines were developed using current Good Manufacturing Processes enabling easy transition into the clinic, and they are extensively characterized with documented and publicly available genomic sequences. These cell lines have also been approved by the National Institutes of Health (NIH) and are included in the NIH Stem Cell Registry. The ESI hES cell lines are available for sale through BioTime.

We also market clonal hES-derived embryonic progenitor (hEP) cells for research purposes developed using ACTCellerate™ technology. We have derived >200 diverse hEP cell types with a wide array of applications research, drug discovery, and human regenerative stem cell therapies.

BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in the United States in collaboration with Hospira and in South Korea under an agreement with CJ Corporation.

Additional products in development by BioTime and its subsidiaries include HyStem®-Rx, a patented hyaluronan-based hydrogel device for cell delivery, and PanC-Dx™, a blood-based pan-cancer screening diagnostic.

BioTime was incorporated in the state of California in 1990 and is a publicly traded company listed on the NYSE Amex stock exchange under the symbol BTX. Our headquarters are located in Alameda, California. We also have subsidiary offices located in Singapore, China, and Israel.